What’s Moving These Biotech Stocks? – Novo Nordisk (NVO), Peregrine Pharmaceuticals (PPHM)

Typically, it doesn’t take a lot for a stock to trade with gains/losses of more than 5% in a session; it can be caused by an analyst’s remarks, sometimes it’s caused by earnings, or maybe it’s just a technical response. Sometimes the moves are warranted and other times they are not. Therefore, I am looking at several moves to determine if the stocks are presenting value or a value trap.

Novo Nordisk A/S (ADR) (NYSE:NVO)

Stock Rallies on Acquisition Rumors

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) began the session with gains of 7% but then traded lower to maintain gains of 3% on Monday. The gains were caused by news that Sanofi SA (ADR) (NYSE:SNY) is aiming to buy another $500 million worth of shares in the open market. The two companies are already partners, and Sanofi is limited to the size of its investment. Sanofi has already said that it does not wish to purchase a controlling stake but judging the by the performance of the stock, investors seem to believe that Sanofi might be preparing for an acquisition offer. Regeneron does look expensive to the naked eye, but is consistent with that of other companies that have approved Orphan drugs and others in its pipeline. The company’s growing fast and is much more stable than others with the same valuation. Therefore, I think the stock might be worth buying on this news.

A Volatile Stock Rallies for No Reason

After a volatile year, shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) traded higher by 5% on Monday. The stock rallied on no news but continues to trade in a steady range. At this point, I don’t trust the company. First, there were problems with the clinical study then the study was less affected than thought. There seems to be a lot of inconsistencies, therefore if data is positive for Bavituximab then I would rather pay a higher premium later then buy for a discount now.

Investors Take Profits & Stock Creates Value

European drug maker Novo Nordisk A/S (ADR) (NYSE:NVO) fell 14% on Monday after federal regulators asked for more testing for its diabetes drug. Now, I understand that a diabetes drug has sales potential in the billions, probably over $2 billion. However, this is a massive company that has several drugs that focus on the treatment of diabetes. The company has more than $13.5 billion in revenue and is growing by 15% year-over-year. Therefore, I think the pullback is a great opportunity. The stock had been trading at all-time highs, and it appears that the loss is more of a technical pullback from the stock having two decades of nothing but gains. I would buy on this news.

Buy on Fundamentals & Not Speculation

While Novo sunk lower, large cap stock Sanofi SA (ADR) (NYSE:SNY) rallied 3.5% on news that it was increasing its stake in Regeneron. For the last year many have speculated that it could try and acquire the biotechnology company, and I believe it’s highly likely. However, you should never buy a stock due to the anticipation of an acquisition; it has to be for fundamental reasons. Therefore, buy the stock for its 3.60% yield, its large cash position, and its strong pipeline. If the acquisition occurs then it’s an added bonus.

Conclusion

A stock’s performance during a typical day does not necessarily mean that a stock will break out or trade lower over a period of time. Too often we associate stock performance with fundamental performance, yet it’s the inconsistencies between these two factors that create value. The ability to identify these inconsistencies is a psychological behavior-changing skill that very few investors are able to perfect. In the past, I have talked about this subject in great detail, and have taught investors how to change these tendencies to return large gains. My advice is to become a smart investor, by learning how to logically assess what caused a stock to move compared to its valuation. Then, if there is a distinction in value you are able to capitalize on the value.

The article What’s Moving These Biotech Stocks? originally appeared on Fool.com and is written by Brian Nichols.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

7 High-Paying Jobs You Can Do From Home

12 Best Cities to Shop in USA

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!